Skip Navigation


Carcinogenesis Advance Access originally published online on November 21, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
25/3/369    most recent
bgh027v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Matakidou, A.
Right arrow Articles by Foulkes, W. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matakidou, A.
Right arrow Articles by Foulkes, W. D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 25, No. 3, 369-373, March 2004
Carcinogenesis vol.25 no.3 © Oxford University Press 2004; all rights reserved.


MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION

Risk of non-medullary thyroid cancer influenced by polymorphic variation in the thyroglobulin gene

Athena Matakidou1,2, Nancy Hamel3, Sanjay Popat1, Kiersten Henderson3, Tania Kantemiroff3, Clive Harmer5, Susan E.M. Clarke6, Richard S. Houlston1,8 and William D. Foulkes3,4,7

1 Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK, 2 Department of Medicine, Royal Marsden Hospital NHS Trust, SM2 5TT, UK, 3 Cancer Prevention Center, Sir MB Davis—Jewish General Hospital, McGill University, Montreal, Quebec, H3T 1E2, Canada, 4 Division of Medical Genetics, Department of Medicine, Research Institute of the McGill University Montreal General Hospital Research Institute, Montreal, Quebec, H3G 1A2, Canada, 5 Department of Clinical Oncology, Royal Marsden Hospital NHS Trust, SM2 5NG, UK, 6 Department of Nuclear Medicine, Guy's and St Thomas' Hospital, London SE1 9RT, UK and 7 Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, Quebec, H2W 1S6, Canada

Benign thyroid disorders are strong risk factors for non-medullary thyroid cancer (NMTC). Germline variation in Tg (thyroglobulin) and TSHR (thyroid stimulating hormone receptor) confers an increased risk of benign thyroid disorders. To explore the hypothesis that polymorphic variation in these genes affects the risk of NMTC we compared the frequency of TgQ2511R, TSHR-P52T and TSHR-D727E genotypes in two series of NMTC cases and controls (group 1, Canadian 102 cases and 102 controls; group 2, British 202 cases and 298 controls). No significant association was seen with TSHR-P52T and TSHR-D727E genotypes and risk of NMTC. However, the frequency of the R-allele of TgQ2511R was over represented in NMTC cases in both study populations. The odds ratios associated with hetero- and homozygosity for the R-allele were 1.6 (95% confidence interval, 1.1–2.5) and 2.0 (95% confidence interval, 1.2–3.3), respectively. Although the risk of NMTC associated with the TgQ2511R R-allele is modest, its high prevalence in the general population suggests it may make a significant contribution to the incidence of NMTC.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
JNCI J Natl Cancer InstHome page
L. Bethke, A. Murray, E. Webb, M. Schoemaker, K. Muir, P. McKinney, S. Hepworth, P. Dimitropoulou, A. Lophatananon, M. Feychting, et al.
Comprehensive Analysis of DNA Repair Gene Variants and Risk of Meningioma
J Natl Cancer Inst, February 20, 2008; 100(4): 270 - 276.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
A. Baida, S. M. Farrington, P. Galofre, R. Marcos, and A. Velazquez
Thyroid Cancer Susceptibility and THRA1 and BAT-40 Repeats Polymorphisms
Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 638 - 642.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.